Cognitive practice effects (PEs) are often ignored and likely delay detection of mild cognitive impairment (MCI). The replacement-participants method of PE adjustment subtracts the scores of demographically-matched, test naïve, replacement participants from returnees’ follow-up scores. The aims of this project were to determine whether this PE adjustment: 1) results in earlier MCI detection; 2) improves diagnostic stability, accuracy, and validity based on concordance with Alzheimer’s disease biomarkers; and 3) reduces costs of clinical trials. The method was adapted for studies that did not recruit replacement participants by identifying “pseudo-replacements”, a subset of baseline participants that are demographically-matched to returnees ...
BACKGROUND: Practice effects (PE), after repeated cognitive measurements, may mask cognitive decline...
With an aging population and an increasing number of individuals with Alzheimer’s disease (AD), a co...
OBJECTIVE: To determine the time required for a preclinical Alzheimer disease population to decline ...
Cognitive practice effects (PEs) are often ignored and likely delay detection of mild cognitive impa...
IntroductionPractice effects (PEs) on cognitive tests obscure decline, thereby delaying detection of...
ObjectiveCognitive practice effects (PEs) can delay detection of progression from cognitively unimpa...
Background: Practice effects (PEs) are improvements in performance after repeated exposure to test m...
Introduction: We investigated whether monthly assessments of a computerized cognitive composite (C3)...
IntroductionLongitudinal testing is necessary to accurately measure cognitive change. However, repea...
INTRODUCTION: Longitudinal testing is necessary to accurately measure cognitive change. However, rep...
Background: Ideally putative disease-modifying therapies for Alzheimer's disease (AD) should be test...
Objectives: A phase of mild cognitive impairment (MCI) precedes most forms of neurodegenerative deme...
OBJECTIVE:To describe the presence of practice effects in persons with Alzheimer disease (AD) or mil...
Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a pr...
OBJECTIVES:A phase of mild cognitive impairment (MCI) precedes most forms of neurodegenerative demen...
BACKGROUND: Practice effects (PE), after repeated cognitive measurements, may mask cognitive decline...
With an aging population and an increasing number of individuals with Alzheimer’s disease (AD), a co...
OBJECTIVE: To determine the time required for a preclinical Alzheimer disease population to decline ...
Cognitive practice effects (PEs) are often ignored and likely delay detection of mild cognitive impa...
IntroductionPractice effects (PEs) on cognitive tests obscure decline, thereby delaying detection of...
ObjectiveCognitive practice effects (PEs) can delay detection of progression from cognitively unimpa...
Background: Practice effects (PEs) are improvements in performance after repeated exposure to test m...
Introduction: We investigated whether monthly assessments of a computerized cognitive composite (C3)...
IntroductionLongitudinal testing is necessary to accurately measure cognitive change. However, repea...
INTRODUCTION: Longitudinal testing is necessary to accurately measure cognitive change. However, rep...
Background: Ideally putative disease-modifying therapies for Alzheimer's disease (AD) should be test...
Objectives: A phase of mild cognitive impairment (MCI) precedes most forms of neurodegenerative deme...
OBJECTIVE:To describe the presence of practice effects in persons with Alzheimer disease (AD) or mil...
Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a pr...
OBJECTIVES:A phase of mild cognitive impairment (MCI) precedes most forms of neurodegenerative demen...
BACKGROUND: Practice effects (PE), after repeated cognitive measurements, may mask cognitive decline...
With an aging population and an increasing number of individuals with Alzheimer’s disease (AD), a co...
OBJECTIVE: To determine the time required for a preclinical Alzheimer disease population to decline ...